- Guide to PHARMACOLOGY
Synonyms: GSK573719A | Incruse Ellipta®
umeclidinium is an approved drug (FDA (2013), EMA (2014))
Compound class: Synthetic organic
Comment: The compound approved in Anoro Ellipta® is umeclidinium bromide (PubChem CID 11519069), and this preparation is documented in the INN record. We display the parent compound here.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: umeclidinium
1. Feldman GJ, Edin A. (2013)
The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Ther Adv Respir Dis, 7 (6): 311-9. [PMID:24004659]
2. Lainé DI, McCleland B, Thomas S, Neipp C, Underwood B, Dufour J, Widdowson KL, Palovich MR, Blaney FE, Foley JJ et al.. (2009)
Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.
J Med Chem, 52 (8): 2493-505. [PMID:19317446]
3. Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ et al.. (2013)
Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.
J Pharmacol Exp Ther, 345 (2): 260-70. [PMID:23435542]